Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors

被引：0
|
作者：
Abou Jokh Casas, E. [1 ]
Pombo Pasin, M. D. [1 ]
Pubul Nunez, V. [1 ]
Garrido Pumar, M. [1 ]
Blanco Freire, M. N. [1 ]
Cabezas, J. [1 ]
Cameselle, J. [1 ]
Berrios, M. [1 ]
Argibay, S. [1 ]
Ruibal Morell, A. [1 ]
机构：
[1] Complejo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0742
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [1] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Wolin, Edward M.
    Hamiditabar, Mohammadali
    Espenan, Gregory D.
    Erion, Jack L.
    O'Dorisio, Thomas M.
    Kvols, Larry K.
    Simon, Jaime
    Wolfangel, Robert
    Camp, Arthur
    Krenning, Eric P.
    Mojtahedi, Alireza
    PANCREAS, 2014, 43 (04) : 518 - 525
  • [2] Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors
    Hamiditabar, Mohammadali
    Ali, Muzammil
    Bolek, Luke
    Vahdati, Gelareh
    Tworowska, Izabela
    Delpassand, Ebrahim S.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (11) : 822 - 828
  • [3] Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours
    Bodei, L.
    Cremonesi, M.
    Grana, C.
    Bartolomei, M.
    Baio, S.
    Bufi, G.
    Fiorenza, M.
    Obenaus, E.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S214 - S214
  • [4] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [5] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599
  • [6] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
  • [7] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, U. M. M.
    Ilan, E.
    Sandstrom, M.
    Bamerny, M.
    Garske-Roman, U.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
  • [8] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [9] Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
    Hidayati, N. R.
    Poon, A.
    Willowson, K.
    Eslick, E.
    Ryu, H.
    Bailey, D. L.
    ATOM INDONESIA, 2019, 45 (03) : 147 - 152
  • [10] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors
    Jahn, U. M. M.
    Jahn, U. M.
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Velikyan, I.
    Fross-Baron, K.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S61 - S62
12345